The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BSE has received a disclosure under Regulation 29(2) of SEBI's Substantial Acquisition of Shares & Takeovers Regulations, 2011, filed by Jagdish Umakant Nayak in relation to Clinitech Laboratory Ltd. This regulation is triggered when a promoter or significant shareholder acquires or disposes of 2% or more of the company's shareholding. The filing confirms that the required disclosure has been submitted to the exchange. No specific details about the direction (buy/sell), number of shares, or revised shareholding percentage are provided in the headline.
This is a routine regulatory disclosure and does not by itself indicate a major shift in ownership. Shareholders should review the actual disclosure to understand whether the insider is increasing or reducing their stake, which could influence short-term sentiment.